Literature DB >> 2293559

Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.

R J Fram1, B A Woda, J M Wilson, N Robichaud.   

Abstract

To study mechanisms underlying resistance to cis-diamminedichloroplatinum (II) (cis-DDP) we have induced resistance to this agent in BE human colon carcinoma cells. A 5-fold increase in the IC50 of resistant compared to sensitive cells was noted as analyzed by the inhibition of cellular growth. Up to a 4-fold reduction in interstrand cross-link formation by cis-DDP in resistant compared to sensitive cells was present as measured by alkaline elution. No significant differences were detectable either in the extent of DNA platination as analyzed by atomic absorption spectroscopy or in the induction of cis-DDP DNA adducts as evaluated by an enzyme-linked immunosorbent assay employing antiserum that detects intrastrand cross-links formed by cis-DDP. Further, no differences in the kinetics of excision of DNA interstrand cross-links, cis-DDP DNA adducts, or total platinum in DNA were present. Levels of glutathione, however, were increased about threefold in resistant compared to sensitive cells. Loss of resistance was associated with increased interstrand cross-link formation and declines in glutathione levels. Our results are consistent with a critical role of glutathione in preventing platinum monoadduct rearrangements resulting in lower levels of interstrand cross-links and resistance to cis-DDP in resistant BE cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293559

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The interaction of DNA-targeted platinum phenanthridinium complexes with DNA.

Authors:  J Whittaker; W D McFadyen; G Wickham; L P Wakelin; V Murray
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

Review 2.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

3.  Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Authors:  H P Hofs; D J Wagener; V de Valk-Bakker; H van Rennes; A J van Zeist; L A van den Broek; H C Ottenheijm
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.

Authors:  M A Alaoui-Jamali; L Panasci; G M Centurioni; R Schecter; S Lehnert; G Batist
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

Authors:  K J Mellish; L R Kelland; K R Harrap
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

6.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

7.  Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

Authors:  M W Sark; H Timmer-Bosscha; C Meijer; D R Uges; W J Sluiter; W H Peters; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

8.  Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.

Authors:  T Misawa; F Kikkawa; O Maeda; N H Obata; K Higashide; N Suganuma; Y Tomoda
Journal:  Jpn J Cancer Res       Date:  1995-01

9.  The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).

Authors:  T Ohmori; T Morikage; Y Sugimoto; Y Fujiwara; K Kasahara; K Nishio; S Ohta; Y Sasaki; T Takahashi; N Saijo
Journal:  Jpn J Cancer Res       Date:  1993-01

10.  Inhibition of cisplatin-mediated DNA damage in vitro by ribonucleotides.

Authors:  S Seki; A Hongo; B Zhang; K Akiyama; A H Sarker; T Kudo
Journal:  Jpn J Cancer Res       Date:  1993-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.